VERAXA Biotech (NASDAQ: VRXA) unveiled the first in vivo proof-of-concept data for its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. The results, which also included additional in vitro findings, mark a significant step toward validating a next-generation approach to antibody-drug conjugates (ADCs) that could improve both efficacy and safety in cancer treatment.
In the in vivo study, a single 3 mg/kg dose of the BiTAC-ADC produced significant tumor regression in a breast cancer model, with no observed decrease in body weight. Notably, both components of the BiTAC-ADC were required to achieve the intended tumor-specific response, confirming the platform’s dual-targeting mechanism. These findings are critical because they demonstrate that the platform can shrink tumors in a living organism, a key milestone for any therapeutic candidate.
Additional in vitro studies showed that the platform can distinguish cancer cells from healthy cells, prevent the release of active toxins outside the tumor, and target multiple cancer cell lines. This suggests that BiTAC-ADCs may deliver efficacy comparable to conventional ADCs while offering a differentiated safety profile designed to reduce systemic toxicity. For patients, this could mean fewer side effects and better tolerability, addressing a major limitation of existing ADC therapies.
The announcement is important because it provides the first in vivo evidence that the BiTAC-ADC platform works as intended, potentially positioning VERAXA Biotech as a leader in the development of safer, more targeted cancer therapies. The data also support the company’s broader pipeline of antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs. As the biotech industry continues to seek ways to improve the therapeutic index of ADCs, VERAXA’s approach could offer a new path forward.
For a deeper look at VERAXA Biotech’s progress, the full press release is available at https://ibn.fm/cs8SW, and the company’s latest news and updates can be found in its newsroom at https://ibn.fm/VRXA. The original release was distributed by NEWMEDIAWIRE.
